Results for tag: "PARP Inhibitor Biomarkers"

In the field of oncology, PARP inhibitors have emerged as a notable class of targeted cancer therapy, particularly for patients with specific biomarker characteristics. These drugs target poly (ADP-ribose) polymerase (PARP), an enzyme that plays a crucial role in the DNA damage repair process in cells. The effectiveness of PARP inhibitors is often linked to the presence of biomarkers such as BRCA1 and BRCA2 mutations, which are indicative of deficiencies in the homologous recombination DNA repair pathway. As a result, the development of PARP inhibitor biomarkers has become integral for the personalized treatment of various cancers, including ovarian, breast, and prostate cancers. Biomarker testing allows for the identification of patients likely to benefit from PARP inhibition, making it an important aspect of precision medicine. The market for PARP inhibitor biomarkers consists of products and services related to the identification, validation, and utilization of these biomarkers in clinical practice. Leading companies in the PARP inhibitor biomarkers market include AstraZeneca, with Lynparza (olaparib); GlaxoSmithKline, which offers Zejula (niraparib); Pfizer's Talzenna (talazoparib); and Clovis Oncology, which markets Rubraca (rucaparib). These companies are at the forefront of innovation in this therapeutic area, continually researching and developing novel biomarker-driven therapies to improve patient care in oncology. Show Less Read more